Ποια είναι η τιμή για Clover Biopharmaceuticals, Ltd. (2197)

Η τιμή για Clover Biopharmaceuticals, Ltd. (2197) είναι $0.25841098

Ποια είναι η κεφαλαιοποίηση αγοράς για Clover Biopharmaceuticals, Ltd. (2197)

Η κεφαλαιοποίηση αγοράς για Clover Biopharmaceuticals, Ltd. (2197) είναι $335.38M

Clover Biopharmaceuticals, Ltd. (2197) Διαίρεση Μετοχών

Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.